First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Telix Pharmaceuticals announces the first U.S. patients have been dosed in the Company’s Phase III ZIRCON trial.
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer imaging product using multi-Curie quantities of cyclotron-produced Gallium-68 via ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target system.
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field of urologic oncology.
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer imaging product.
Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product
Telix has been granted HREC approval and received CTN clearance by the TGA to commence Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients with advanced prostate cancer.
Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe
Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from the Walloon regional government in Belgium.
Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery
Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate cancer.
Completion of Phase I Enrolment of Japanese Renal Cancer Study
Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan.
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical trial
First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic